FMP

FMP

Enter

ETON - Eton Pharmaceut...

photo-url-https://images.financialmodelingprep.com/symbol/ETON.png

Eton Pharmaceuticals, Inc.

ETON

NASDAQ

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

11.23 USD

0.48 (4.27%)

About

ceo

Mr. Sean E. Brynjelsen

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in c...

CIK

0001710340

ISIN

US29772L1089

CUSIP

29772L108

Address

21925 West Field Parkway

Phone

847 787 7361

Country

US

Employee

30

IPO Date

Nov 13, 2018

ETON Financial Summary

CIK

0001710340

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

29772L108

ISIN

US29772L1089

Country

US

Price

11.23

Beta

1.26

Volume Avg.

190.59k

Market Cap

290.14M

Shares

-

52-Week

3.03-11.44

DCF

3.6

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-53.48

P/B

-

Website

https://www.etonpharma.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest ETON News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep